A detailed history of Global Retirement Partners, LLC transactions in Genmab A/S stock. As of the latest transaction made, Global Retirement Partners, LLC holds 4,886 shares of GMAB stock, worth $102,703. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,886
Previous 4,233 15.43%
Holding current value
$102,703
Previous $106,000 12.26%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$23.84 - $28.48 $15,567 - $18,597
653 Added 15.43%
4,886 $119,000
Q2 2024

Jul 23, 2024

BUY
$25.13 - $30.27 $92,076 - $110,909
3,664 Added 643.94%
4,233 $106,000
Q1 2024

Apr 23, 2024

SELL
$26.43 - $32.77 $475 - $589
-18 Reduced 3.07%
569 $17,000
Q4 2023

Jan 18, 2024

BUY
$27.94 - $35.44 $3,185 - $4,040
114 Added 24.1%
587 $18,000
Q3 2023

Oct 13, 2023

BUY
$35.27 - $42.24 $3,491 - $4,181
99 Added 26.47%
473 $16,000
Q1 2023

May 05, 2023

SELL
$34.88 - $43.22 $1,430 - $1,772
-41 Reduced 9.88%
374 $14,000
Q4 2022

Feb 13, 2023

SELL
$33.8 - $47.06 $642 - $894
-19 Reduced 4.38%
415 $17,000
Q3 2022

Nov 03, 2022

BUY
$31.52 - $373.61 $4,192 - $49,690
133 Added 44.19%
434 $17,000
Q2 2022

Jul 15, 2022

BUY
$26.83 - $38.57 $3,407 - $4,898
127 Added 72.99%
301 $10,000
Q1 2022

Jul 14, 2022

BUY
$30.95 - $39.68 $5,385 - $6,904
174 New
174 $5,000
Q4 2021

Jan 21, 2022

SELL
$35.87 - $47.12 $2,654 - $3,486
-74 Closed
0 $0
Q3 2021

Oct 22, 2021

BUY
$41.55 - $48.72 $457 - $535
11 Added 17.46%
74 $3,000
Q2 2021

Jul 15, 2021

BUY
$32.88 - $44.57 $2,071 - $2,807
63 New
63 $3,000
Q4 2020

Jan 13, 2021

SELL
$33.66 - $40.76 $3,736 - $4,524
-111 Closed
0 $0
Q3 2020

Oct 09, 2020

BUY
$33.07 - $38.68 $3,670 - $4,293
111 New
111 $4,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.8B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Global Retirement Partners, LLC Portfolio

Follow Global Retirement Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Global Retirement Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Global Retirement Partners, LLC with notifications on news.